No benefit to continue lamivudine therapy after emergence of YMDD mutations

Antiviral Therapy

Volumn 9, Issue 2, 2004, Pages 257-262

  Liaw, Yun Fan ^a   Chien, Rong Nan ^a   Yeh, Chau Ting ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE LOCUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT FAILURE; VIRUS MUTATION;

ADOLESCENT; ADULT; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TREATMENT OUTCOME;

EID: 2342430923     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Doong SL, Tsia CH, Schinazi RF, Liotta DC & Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′ -dideoxy-3′thiacytidine and related analogues. Proceedings of the National Academy of Sciences, USA 1991; 88:8495-8499.
2. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, Tennant B, Frick L, Averett D, Condreay LD & Jilbert AR. Lamivudine therapy of WHV-infected woodchucks. Virology 1998; 245:18-32.
3. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DY, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL. Asian hepatitis lamivudine study group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
4. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL & Gray DF. A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 1998; 339:61-68.
5. Si Ahmed SN, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C & Zoulim F. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32:1078-1088.
6. Core working party for Asia-Pacific consensus on hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Journal of Gastroenterology & Hepatology 2000; 15:825-841.
7. Lok ASF & McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
8. Melegari M, Scaglioni PP & Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
9. Lim SG, Wai CT, Rajnakova A, Kajiji T & Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51:597-599.
10. Liaw YF, Chien RN, Yeh CT, Tsai SL & Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
11. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
12. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V & Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219-226.
13. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD & Chien RN. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
14. DeMan RA, Bartholomeusz AI, Niesters HGM, Zonderan PE & Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. Journal of Hepatology 1998; 29:669-675.
15. Malik AH & Lee WM. Hepatitis B therapy: the plot thickens. Hepatology 1999; 30:579-581.
16. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ & Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999; 29:939-945.
17. Yeh CT, Chien RN, Chu CM & Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
18. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP & Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
19. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L & Brown N. Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-432.
20. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER & Rutkiewicz V. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34:340A.
21. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti-hepatitis B virus therapy. Journal of Gastroenterology & Hepatology 2003; 18:246-252.
22. Leung NW, Liaw YF, Chang TT, Guan R, Lee CM, Lim SG et al. Durable HBeAg response in Chinese patients treated with lamivudine. Hepatology 2001; 34:348A. Abstract 705.
23. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R & Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clinical Infectious Disease 2003; 36:687-696.
24. Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC & Liaw YF. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. Journal of Biomedical Science 2003; 10:120-135.
25. Wang JH, Lu SN, Lee CM, Lee JF & Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scandinavian Journal of Gastroenterology 2002; 37:366-369.
26. Wong VWS, Chan HLY, Wong ML & Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? Journal of Hepatology 2002; 36:177. Abstract 625.